SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

APLD is trending as investors anticipate earnings, with many hoping for news on potential hyperscaler deals that could boost AI infrastructure growth. Community discussions center on the timing of a new lease and the impact of Macquarie's recent funding draw. Bullish sentiment remains strong due to expectations for increased AI data center demand and APLD's strategic positioning in the sector.

SEALSQ Corp. is a holding company, which engages in the security of microcontrollers. It operates through the following geographical segments: North America, Europe, Middle East, Africa, Asia Pacific, and Latin America. It focuses on authentication process, digital certification, and covering individual patents of semiconductors. The company was founded on April 1, 2022 and is headquartered in Cointrin, Switzerland.

SEALSQ Corp

SEALSQ (LAES) is trending due to a strategic partnership to develop 'Made in US' post-quantum cryptography solutions for US government and defense, sparking bullish sentiment. The community is actively discussing the potential for a short squeeze and significant upside, drawing comparisons to other quantum stocks. With high trading volume and positive news, investors are optimistic about the company's future growth and potential double-digit price targets.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath ($PATH) is trending due to a significant surge fueled by new AI partnerships with industry leaders like OpenAI, Google, NVIDIA, and Snowflake. The community is buzzing about the company's shift towards agentic automation and its potential to become a central player in enterprise AI, drawing comparisons to Palantir ($PLTR). Many believe $PATH has been undervalued and are anticipating further gains, citing its strong cash position and strategic partnerships as catalysts for future growth.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. TeraWulf will generate domestically produced bitcoin powered by nuclear, hydro and solar energy. The company was founded by Paul Prager and Nazar Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf ($WULF) is trending as investors discuss a potential short squeeze, fueled by its high short interest and growing optimism around its transition to AI and high-performance computing. Community members are pointing to the stock's setup mirroring past breakouts, while also highlighting analyst price targets and the increasing open interest in call options. Some are closely watching for news regarding the Lake Cayuga site approval, which could act as a further catalyst.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

SLV is trending as silver prices approach multi-decade highs, sparking discussions about a potential breakout. Community members are debating whether demand is crushing short positions and anticipating further gains, with some pointing to a possible short squeeze. The broader context involves rising interest in precious metals as a hedge against economic uncertainty, amplified by a potentially weaker dollar and a possible government shutdown.

TOSHI

TOSHI is trending as the community rallies behind the token, pointing to strong chart patterns and increasing volume. Many are drawing comparisons to previous meme coin surges, speculating on potential listings on major exchanges like Robinhood and Binance. The community emphasizes its strong organic growth and active engagement.

HIVE Digital Technologies Ltd. engages in building a bridge between the digital currency and blockchain sector and traditional capital markets. It operates data centers for computing and mining cryptocurrencies, including Bitcoin and other coins. The firm owns and operates green energy-powered data center facilities in Canada, Sweden, and Iceland. Its project includes Iceland Cryptocurrency Mining. HIVE Digital Technologies was founded on June 24, 1987 and is headquartered in San Antonio, TX.

HIVE Digital Technologies Ltd.

HIVE Digital Technologies Ltd

HIVE Digital Technologies is trending amid increased Bitcoin production and expansion into AI cloud services, sparking community excitement around its potential in both sectors. Some investors are drawing comparisons to IREN, while others highlight HIVE's strong assets and growing hashrate, anticipating further upward momentum. Discussions also focus on potential partnerships and undervaluation relative to peers.

Kratos Defense & Security Solutions, Inc. engages in the provision of mission critical products, services and solutions for United States national security priorities. It operates through the Kratos Government Solutions (KGS) and Unmanned Systems (US) segments. The KGS segment consists of an aggregation of KGS operating segments, including microwave electronic products, space, satellite and cyber, training solutions. The US segment refers to the unmanned aerial, unmanned ground, unmanned seaborne and related command, control and communications system businesses. The company was founded on December 19, 1994, and is headquartered in Round Rock, TX.

Kratos Defense & Security Solutions Inc

Kratos Defense & Security is trending as investors discuss its potential due to increased defense spending and the company's focus on drones and hypersonic technology. Community members are closely watching for upcoming contract announcements and potential partnerships, with some suggesting a significant long-term upside. Recent news highlights Kratos's growing role in advanced defense systems, further fueling optimism.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

NBIS is trending as investors actively discuss the potential impact of data center constraints and new partnerships on the company's growth. Community members are speculating about upcoming news and potential deals, particularly related to its stake in Clickhouse and its role in AI infrastructure. The stock's volatility and potential for significant gains are also prominent talking points.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is trending amid discussions around its valuation, potential for a short squeeze, and a recent healthcare partnership with OneMedNet; the community is debating whether the stock is overvalued and if it can sustain its high growth, while some point to the potential for breakout traders to drive the price higher. Bullish sentiment remains strong despite some concerns about the company's valuation and the sustainability of its growth.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Skye Bioscience, Inc. - SKYE

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Skye Bioscience, Inc. - SKYE INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Skye...

SKYE Stock Plunges 60% as Obesity Candidate Misses Key Phase II Goal

Skye Bioscience stock nosedives 60% after its investigational obesity candidate, nimacimab, fails to meet the key goal in a mid-stage study.

Shares of Skye Bioscience, Inc. (SKYE) dived 60% in the pre-market session on Monday after the company said that its Nimacimab alone did not cause weight loss as compared to placebo in a mid-stage trial.Preliminary analysis suggested that 200 mg of Nimacimab as a subcutaneous weekly dose was suboptimal as a monotherapy, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.skyebioscience.com/news-releases/detail/244/skye-bioscience-reports-topline-cbeyond-phase-2a-data-from-nimacimab-monotherapy-and-combination-clinical-trial">said</a>. The data, however, support the evaluation of higher dosing, the company said.Further, Nimacimab in combination with Novo Nordisk’s Semaglutide demonstrated a clinically meaningful magnitude of weight loss compared to Semaglutide alone, the company said. The positive observation supports further studies where Nimacimab is used with other therapies, it added.The drug alone and in combination demonstrated a clean safety profile, with no added gastrointestinal adverse events and no increases in neuropsychiatric adverse events reported resulting from treatment with Nimacimab, Skye said. Overall, the study, which enrolled 136 adults with overweight or obesity, had a discontinuation rate of 27%. Notably, 3.7% of the discontinuations were due to adverse events, with the placebo group contributing 60% of these discontinuations, according to the company.“With our preclinical data, toxicology safety margins, and PK modeling, we believe we have a path to support higher dosing, and we are evaluating the next stage of development to optimize dosing in potential future clinical trials," said Puneet Arora, Chief Medical Officer of Skye Bioscience. The company is now evaluating the data to determine the next steps for the development of the drug.SKYE stock is up 68% this year and by about 24% over the past 12 months.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Why Did Skye Bioscience Stock Plummet A Whopping 60% Today?

The company stated that its investigational drug alone did not cause weight loss compared to the placebo in a mid-stage trial. 

Equity

The company stated that its investigational drug alone did not cause weight loss compared to the placebo in a mid-stage trial. 


The broader market experienced mixed performance on Monday, with major indices showing volatility but ultimately closing higher. The Dow Jones Industrial Average gained 0.78%. The S&amp;P 500 rose 0.79%, and the Nasdaq Composite climbed 0.64%. However, all three major averages were in the red at one point during the trading session. Despite this, the stocks making moves on market news continued to captivate investors with their dynamic performances and strategic advancements. In this article, we will take a look at the 6 best stocks that were making moves on market news with their groundbreaking innovations and strategic advancements.Also Read: <a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/stocks/biotech/quantum-biopharma-expands-reach-with-new-unbuzzd-launch-and-cutting-edge-ms-clinical-study/">This Low-Float Biotech Stock is making waves with an advanced MS diagnostic tool</a><a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/newsletter-sign-up/">Our email list eats first! Get exclusive alerts on explosive stock picks like AST SpaceMobile (NASDAQ: ASTS), which shot up +533% after our profile. Get our email signals based on our proprietary 5-indicator system before any of our other platforms by clicking here.</a><h3>1. Recursion Pharmaceuticals (RXRX)&nbsp;&nbsp;</h3>Market Cap as of April 15: $2.34 Billion&nbsp;&nbsp;Recursion Pharmaceuticals (NASDAQ: RXRX) is a clinical-stage biotechnology company that leverages artificial intelligence and automation to discover and develop novel therapeutics across a wide range of diseases.First Patient Dosed: Recursion Pharmaceuticals has recently announced the dosing of the first patient in its early-stage study of REC-3565 for treating relapsed or refractory B-cell lymphomas, which marks a significant clinical milestone.Unique Mechanism: REC-3565 has a unique mechanism of action that reduces the risk of drug-drug interactions and hyperbilirubinemia, making it potentially safer and more effective.Preclinical Success: Preclinical studies showed durable tumor regressions with REC-3565, both as monotherapy and in combination with a BTK inhibitor, which indicates strong clinical efficacy.Industry Collaborations: The company has partnerships with major pharmaceutical companies such as Roche, Bayer, Merck, and Sanofi, which provides it with additional resources and market access.FDA Policy Shift: The FDA has also announced to phase out some animal testing requirements for monoclonal antibodies, which benefits RXRX’s AI-driven platform.Stock Performance:Recursion Pharmaceuticals has shown strong weekly performance with a 45.26% gain. However, it has underperformed in the month and year, with declines of 15.69% and 31.43%, respectively.<h3>2. Certara (CERT)&nbsp;&nbsp;</h3>Market Cap as of April 15: $2.29 Billion&nbsp;&nbsp;Certara (NASDAQ: CERT) provides biosimulation software and technology-driven solutions to improve the drug development process, helping biopharma companies optimize clinical outcomes.Strong First Quarter Financial Results: On April 14, Certara reported preliminary first-quarter 2025 financial results.&nbsp; The company reported a 10% revenue growth to $106.0 million compared to the first quarter of 2024, with software revenue growing by 18% to $46.4 million.Bookings Growth: The company’s bookings increased by 12% to $118 million, with software bookings growing by 22% to 40.6 million.Adjusted EBITDA Growth: Adjusted EBITDA is expected to be in the range of $33 million to $35 million, representing a 13-20% growth compared to the first quarter of 2024.Reiteration of Full-Year Guidance: Certara reiterated its full-year 2025 guidance, projecting revenue in the range of $415 million to 425 million, an adjusted EBITDA margin of 30-32%, and adjusted diluted earnings per share of 42 to 46 cents.Stock Repurchase Authorization: The Board of Directors authorized a stock repurchase program of up to $100 million, reflecting confidence in the company’s strategy and financial performance.Non-Animal Navigator Launch: Certara launched its Non-Animal Navigator solution to help biopharmaceutical companies reduce reliance on animal testing by offering strategic regulatory advice, integrated preclinical development plans, and optimized AI-enabled modeling tools.Industry Adoption: The growing industry adoption of new approach methodologies (NAMs) like AI-enabled biosimulation supports Certara’s strategic focus and enhances its competitive position.Stock Performance:Certara has had a robust week with a 57.18% increase. However, it has faced losses over longer periods, including a 19.50% decline in performance year-to-date.<h3>3. United States Antimony (UAMY)&nbsp;&nbsp;</h3>Market Cap as of April 15: $377.72 Million&nbsp;&nbsp;United States Antimony (NYSEAMERICAN: UAMY) is involved in the mining, production, and sale of antimony and zeolite products, which are used in flame retardants, batteries, and chemical applications.Lease/Option Purchase Agreement: United States Antimony has executed a new lease/option purchase agreement with an experienced prospector in Wasilla, Alaska, for lands adjacent to existing leased and staked claims, with new claims and leases totaling 17,900 acres in the Fairbanks area and 3,840 acres near Stibnite Creek.Exploration Focus: Plans to begin high-grade stibnite exploration and mining operations in early May in the Fairbanks area. Management aims to extract antimony ore from its own mining claims in Alaska to Montana by Q3 2025.Antimony Production and Global Supply: China is the world’s top producer of antimony, but its output has been declining over the past decade, making it difficult to meet global needs without new sources. Furthermore, Antimony prices have surged due to China’s export ban, which began in December 2024.Montana Smelters: The company operates two smelters in Montana with capacities of 3,840tpa and 2,400tpa for antimony processing.Stock Performance:United States Antimony has demonstrated exceptional growth across various periods, including a strong weekly gain of 66.92%. It has also seen a remarkable year-over-year growth of 1,239.51%.&nbsp;Read Now: <a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/stocks/tech/u-power-makes-waves-at-bangkok-motor-show-with-groundbreaking-battery-swap-demo/">Electric Vehicle Player Is Making Waves With Groundbreaking Battery Swapping Technology</a><a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/newsletter-sign-up/">Our email list eats first! Get exclusive alerts on explosive stock picks like AST SpaceMobile (NASDAQ: ASTS), which shot up +533% after our profile. Get our email signals based on our proprietary 5-indicator system before any of our other platforms by clicking here.</a><h3>4. Janover (JNVR)&nbsp;&nbsp;</h3>Market Cap as of April 15: $106.54 Million&nbsp;&nbsp;Janover (NASDAQ: JNVR) provides online platforms for commercial real estate and small business loans, connecting borrowers with lenders using data-driven digital solutions.New Treasury Strategy: Janover announced a new treasury policy on April 4, 2025, to accumulate crypto assets, starting with Solana (SOL). This strategy aligns with the company’s goal of providing investors economic exposure to SOL.Significant SOL Purchases: Janover made substantial purchases of Solana (SOL) tokens, totaling $21.2 million across three transactions. These purchases have brought the company’s total SOL holdings to 163,651.7.Staking and Revenue Generation: The company will begin staking its SOL position immediately, generating revenue while supporting the Solana network. Staking rewards are also planned to be reinvested, which will further enhance cryptoasset holdings.Recent Financing Round: Janover has also raised $42 million in a financing round from investors including Pantera Capital and Kraken. These funds are specifically allocated for acquiring digital assets.Stock Performance:Janover has seen explosive growth, with a week-over-week performance of 130.20% and a remarkable 1707.42% increase in the month.<h3>5. Skye Bioscience (SKYE)</h3>Market Cap as of April 15: $82.40 MillionSkye Bioscience (NASDAQ: SKYE) is a pharmaceutical company focused on developing cannabinoid-derived molecules to treat glaucoma and other diseases with unmet medical needs.Significant Weight Loss in Preclinical Study: On April 15, Skye Bioscience announced over 30% weight loss in a diet-induced obesity model when nimacimab was combined with tirzepatide, which showcases its strong efficacy and potential as a combination therapy.Comparable Efficacy to Monlunabant and Tirzepatide: Nimacimab alone achieved 23.5% weight loss, comparable to other leading obesity drugs like tirzepatide and monlunabant, which indicates robust monotherapy potential.Differentiated Mechanism: Nimacimab’s non-competitive allosteric binding to the CB1 receptor provides a differentiated mechanism compared to monlunabant and has potentially fewer neuropsychiatric side effects.Superior Potency in High Agonist Conditions: In vitro data showed nimacimab’s potency remained stable under high agonist conditions, while monlunabant’s effectiveness was significantly impacted, which indicates superior performance in disease states like obesity.Phase 2a Data: Top-line data from the Phase 2a CBeyond study is expected in late Q3/early Q4 2025, which will provide investors with near-term clinical validation of nimacimab’s efficacy.Focus on Metabolic Health: Skye’s focus on developing next-generation molecules for metabolic health disorders aligns with the growing demand for effective obesity treatments in the market.First-In-Class Therapeutic Potential: Nimacimab’s mechanism of action as a negative allosteric modulating antibody for CB1 inhibition positions it as a first-in-class therapeutic with clinical and commercial differentiation.Stock Performance:Skye Bioscience has had a mixed performance, with a significant weekly gain of 143.32% but a modest monthly gain of only 15.41%.<h3>6. Aerovate Therapeutics (AVTE)</h3>Market Cap as of April 15: $79.12 MillionAerovate Therapeutics (NASDAQ: AVTE) is a biotechnology company developing inhaled therapies for rare cardiopulmonary diseases, with a lead candidate targeting pulmonary arterial hypertension.Expected Cash Dividend: Aerovate Therapeutics expects to declare a cash dividend in the range of $67.6 million to $69.6 million in the aggregate, based on its estimated net cash immediately prior to the closing of its merger with Jade Biosciences, which was announced on October 30, 2024.Merger Status: The Merger remains subject to approval by Aerovate’s stockholders and other closing conditions. The special meeting for stockholder approval is scheduled for April 16, 2025, with the Closing expected on or about April 28, 2025.Dividend Declaration: The official declaration of the Cash Dividend is subject to approval by the Aerovate board of directors and is expected to be announced later this month.Payment Details: The dividend will be paid with an estimated $2.40 per share based on 28,985,019 shares outstanding as of April 9, 2025. The payment date is scheduled for April 29, 2025.Purpose of Merger: The merger will combine Aerovate’s expertise in rare cardiopulmonary diseases with Jade’s focus on developing best-in-class therapies for autoimmune diseases. This combination is expected to create a robust pipeline and enhanced capabilities to address critical unmet medical needs.Stock Performance:Aerovate Therapeutics has exhibited extraordinary performance, with a week-over-week gain of 2914.67% and a month-over-month gain of 2975.95%, making it a standout performer among the stocks listed.<h3>Conclusion</h3>As we conclude our review of these promising companies, it’s clear that these stocks making moves on market news are not just fleeting trends but represent substantial investment opportunities. Each company discussed here is leveraging cutting-edge technology, strategic partnerships, and market shifts to propel their businesses forward, making them standout choices for discerning investors.&nbsp; &nbsp;Read Next: <a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/featured/top-4-stocks-poised-for-big-gains/">4 Stocks Poised for Big Gains Amid Major Transformations</a> &nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/newsletter-sign-up/">Our email list eats first! Get exclusive alerts on explosive stock picks like AST SpaceMobile (NASDAQ: ASTS), which shot up +533% after our profile. Get our email signals based on our proprietary 5-indicator system before any of our other platforms by clicking here.</a><a target="_blank" rel="noopener noreferrer nofollow" href="https://www.facebook.com/groups/WealthyVC">Join the Discussion in the WVC Facebook Investor Group</a>Do you have a stock tip or news story suggestion? Please email us at&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="mailto:Invest@WealthyVC.com">Invest@WealthyVC.com</a>.Disclaimer: Wealthy VC does not hold a position in any of the stocks, ETFs or cryptocurrencies mentioned in this article.

Small Cap News Movers: Your Daily Digest of Stocks Making Moves on Market News

Others

Is This Penny Stock’s 525% Upside Potential an Attainable Goal?

Skye Bioscience is trying to establish a presence in the weight-loss drug market.

Craig-Hallum Keeps Their Buy Rating on Skye Bioscience (SKYE)

Craig-Hallum analyst Albert Lowe maintained a Buy rating on Skye Bioscience (SKYE Research Report) today and set a price target of $18.00. The co...

Skye Bioscience, Inc. (SKYE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Skye Bioscience, Inc. (Skye or the Company) (NASDAQ: SKYE). Investors who...

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Skye Bioscience, Inc. (Skye or the Company) (NASDAQ: SKYE). Investors who...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Skye Bioscience, Inc. - SKYE

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Skye Bioscience, Inc. - SKYE SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of...

Skye Bioscience, Inc. is a clinical stage biopharmaceutical company, which engages in the development of new medicines that unlock the pharmaceutical potential of the endocannabinoid system to treat diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration. Its products include nimacimab and SBI-100 Ophthalmic Emulsion. The company was founded on March 16, 2011 and is headquartered in San Diego, CA.

Skye Bioscience Inc

Will JP Morgan Chase ($JPM) beat quarterly earnings?  
 
*Powered by Polymarket

Stocktwits

JPMorgan Chase & Co

) beat quarterly earnings?  
 
*Powered by Polymarket

SKYE
Skye Bioscience Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SKYE News

SKYE Skye Bioscience Inc